Standardize uptake value of 18F-FDG-PET-CT is in accordance with the 21-gene recurrence score (Oncotype Dx) in ER-positive and HER2-negative breast cancer patients

Is 18FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?

“…In 305 patients with hormone receptor-positive BC, Ahn et al reported that SUV max was correlated with recurrence-free survival (SUV max cutoff value of 4) [8]; 174 women (57 %) had T1 tumour (size ≤ 2 cm). In a recent preliminary report, the same team also suggested that SUV max of 4 to be used as a cutoff value to estimate the Oncotype DX RS (to separate low-tointermediate from high RS) [9]. In the study by Aogi et al [10], 262 stage I-III luminal BC patients (187 with T1 tumour) had 18 FDG-PET/CT before initial therapy.…”

“…The studies from Lee [7], Ahn [8,9] and Aogi [10] are focused on early stage BC. Partial volume effect can affect SUV values.…”